Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Melanoma 3Neoplasm Metastasis 2Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
omaveloxolone × Dermatologic × Clear all
NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

Biogen

Phase 1/2 Completed
41 enrolled 15 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03593499 2025-05-31

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

Biogen

No longer available
Dermatologic

Melanoma

NCT02029729 2025-05-29

DISCOVER

Biogen

Phase 1 Completed
11 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡